Lung Cancer

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the role of liquid biopsies for patients with lung cancer.

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses sequencing challenges for patients with advanced lung cancer.

Combining pembrolizumab with chemotherapy in the frontline setting improved survival in patients with nonsquamous non–small cell lung cancer.

Loretta Erhunmwunsee, MD, thoracic surgeon, assistant professor of surgery, City of Hope, discusses disparities in the treatment of lung cancer.

Paul A. Bunn, Jr, MD, discusses the IMpower150 study and other immunotherapy combinations in NSCLC.

Results from a recent multicenter, retrospective analysis of 242 patients with advanced non–small cell lung cancer (NSCLC) found that 16% developed hyperprogression during anti–PD-1/PD-L1 treatment.

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the FDA approval of afatinib (Gilotrif) for the frontline treatment of patients with metastatic non

The FDA has expanded the frontline indication for afatinib to include the treatment of patients with metastatic non–small cell lung cancer whose tumors harbor uncommon EGFR alterations in L861Q, G719X, and/or S768I.

Lecia V. Sequist, MD, reflects on the practice-changing osimertinib data, ongoing trials exploring combination regimens, and discusses the potential for immunotherapy in EGFR-positive NSCLC.

Amid rapid-fire developments in non–small cell lung cancer (NSCLC) research, the role of checkpoint immunotherapy continues to mature.

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute at Swedish Medical Center, discusses chemotherapy in patients with non

Increasing evidence suggests that immune responses against SCLC cells make immunotherapy a rational approach.

Erminia Massarelli, MD, PhD, discusses the evolving paradigm of ALK-positive non-small cell lung cancer based on recent regulatory decisions and what additional advancements are expected in the year ahead.

Jae Y. Kim, MD, discusses developments with checkpoint inhibition in patients with resectable NSCLC.

Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses recent advancements in squamous cell lung cancer.

Ravi Salgia, MD, PhD, discusses the evolution and current state of biomarker testing in the field of NSCLC.

Dan J. Raz, MD, discusses the ongoing ALCHEMIST trial and some novel techniques, such as tissue slice culture, that are propelling the field of lung cancer forward.

Plinabulin, an antineoplastic agent that activates an immune response, is being investigated as a treatment option for patients with advanced or metastatic non–small cell lung cancer who have progressed after standard-of-care therapy.

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the importance of next-generation sequencing for patients with lung cancer.

Loretta Erhunmwunsee, MD, discusses the racial and socioeconomic disparities in lung cancer trials

Karen Reckamp, MD, discusses positive phase III data, recent regulatory approvals, and what research the new year is likely to bring to the field of non-small cell lung cancer (NSCLC).

Jared Weiss, MD, discusses utilizing liquid biopsies for patients with lung cancer, the pros and cons of the approach, and when it might be appropriate to rebiopsy patients.

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the treatment options for patients with T790M-mutant lung cancer.

Karen Reckamp, MD, MS, medical oncologist, City of Hope, discusses the role of molecular testing for patients with lung cancer.

Kathryn F. Mileham, MD, discusses the development of biomarker testing for patients with mutated non-small cell lung cancer.